

Agenda

2nd Human Antibody Initiative (HAI) workshop

Munich, Saturday 14.30-18.00, August 27, 2005

Purpose of the workshop

- To discuss the aims and milestones for the two subprograms outlined in the Human Antibody Initiative proposal (see HUPO web site)
- To agree on quality assurance requirements for antibodies
- To select members of an executive committee for the initiative (representing the different HUPO regions) and to determine its responsibilities
- To discuss general issues related to the antibody initiative and possible other subprograms in the field of antibody-based proteomics

Preliminary agenda

Session 1. Presentations

Time	Topic	Presenter
14.30	Welcome and introduction	Uhlen, KTH
14.40	Liver proteomics antibodies	Sun, Beijing
14.50	Antibodies from the Beijing Genome Institute	WuLin, BGI
15.00	Antibody generation in the HPR effort	Hober, KTH,
15.10	Example of a commercial effort: mAb (Abnova)	Huang, Abnova
15.20	Example of a commercial effort: pAb (Geneway)	Wei-Wei, Geneway
15.30	The ESF/EU network project	Taussig, Babraham
15.40	The Sanger Center project	Pope, Sanger
15.50	Experience from proteomics databases	Hermjakob, EBI
16.00	The NIH cancer proteomics effort	Downing, NIH
16.10	Live presentation of the Human Protein Atlas	Kampf, UU

16.20-16.30

Break (if time permits)

Session 2. Discussions and decisions

Time	Topic	Decisions
16.30	Antibody resource <ol style="list-style-type: none"> a. Web-submission form (what should be required for submission) b. Quality assurance criteria (antigen, antibody and applications) c. Curation (how to incorporate input from outside, how to exclude antibodies with likely cross-reactivity) d. Time-lines (is the dead-lines realistic, see proposal) e. Responsibility (and possible funding) 	Approve
17.00	Protein atlas <ol style="list-style-type: none"> a. Selection of tissues (representative, should other tissues or diseases be included) b. Antibodies from other groups (rules and requirements) c. Help functions and queries (suggestions) d. Exclusion of antibodies (with likely cross-reactivity) e. Time-lines and deliverables (see proposal) 	Approve
17.30	General issues <ol style="list-style-type: none"> a. Members of the executive committee and their responsibilities b. Vision (see proposal) c. Interaction with other HUPO initiatives d. Other possible initiatives <ol style="list-style-type: none"> i. Immunocapture ii. Protein arrays iii. Modification specific antibodies iv. Others (please suggest) 	Suggest one representative from each HUPO region
18.00	Closing	